Products for Research Use Only

UCL-TRO-1938

CAT: 0804-HY-154848-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-154848-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
UCL-TRO-1938 is a potent small molecule allosteric activator of PI3Kα with an EC50 value of approximately 60 μM. UCL-TRO-1938 can induce cell proliferation and has cardioprotective effects from ischaemia reperfusion injury and enhances nerve regeneration following nerve crush[1][2][3][4][5].
CAS Number
2919575-27-0
UNSPSC
12352005
Target
Akt; PI3K
Type
Reference compound
Related Pathways
PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Neurological Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/ucl-tro-1938.html
Purity
99.98
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 80°C)
Smiles
O=C(C)N1C2=C(CC1)C=CC=C2NC3=CC(NC4=CC=C(N5CCN(CC5)CC)C=C4)=NC=C3
Molecular Formula
C27H32N6O
Molecular Weight
456.58
References & Citations
[1]Gong GQ, et al. A small-molecule PI3Kα activator for cardioprotection and neuroregeneration. Nature. 2023 Jun;618 (7963) :159-168. |[2]Shi H, et al. miR-30c-5p inhibits esophageal squamous cell carcinoma progression by repressing the PI3K/AKT signaling pathway. Thorac Cancer. 2024 Oct;15 (30) :2206-2216. |[3]Najam O. Exploring the role of cardiac mast cells in acute myocardial infarction and ischaemia-reperfusion injury[D]. UCL (University College London), 2023.|[4]Kingwell K. PI3K activator taps route to regeneration. Nat Rev Drug Discov. 2023 Jul;22 (7) :537.|[5]Ni C, et al. An inappropriate decline in ribosome levels drives a diverse set of neurodevelopmental disorders. bioRxiv [Preprint]. 2024 Jan 9:2024.01.09.574708.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported